每(mei)經(jing)AI快訊，9月2日(ri)，先聲藥(yao)業在(zai)港(gang)交所公(gong)告，配(pei)(pei)售(shou)(shou)(shou)現有(you)股(gu)(gu)(gu)份(fen)及(ji)根據一(yi)般(ban)授權先舊后新(xin)認(ren)(ren)購(gou)(gou)新(xin)股(gu)(gu)(gu)份(fen)。于2025年9月2日(ri)（交易時段(duan)前），公(gong)司、賣方(fang)及(ji)配(pei)(pei)售(shou)(shou)(shou)代理(li)訂(ding)立配(pei)(pei)售(shou)(shou)(shou)及(ji)認(ren)(ren)購(gou)(gou)協議，賣方(fang)已有(you)條件同(tong)(tong)意委任摩根士丹利(li)亞洲(zhou)有(you)限公(gong)司擔(dan)任配(pei)(pei)售(shou)(shou)(shou)代理(li)，而配(pei)(pei)售(shou)(shou)(shou)代理(li)已有(you)條件同(tong)(tong)意擔(dan)任賣方(fang)的(de)代理(li)，以促使不少于六名買(mai)方(fang)按配(pei)(pei)售(shou)(shou)(shou)價（即(ji)每(mei)股(gu)(gu)(gu)12.95港(gang)元）購(gou)(gou)買(mai)銷售(shou)(shou)(shou)股(gu)(gu)(gu)份(fen)（即(ji)1.21億股(gu)(gu)(gu)股(gu)(gu)(gu)份(fen)）；及(ji)公(gong)司已有(you)條件同(tong)(tong)意向賣方(fang)發行及(ji)賣方(fang)有(you)條件同(tong)(tong)意以認(ren)(ren)購(gou)(gou)價（相(xiang)(xiang)當(dang)于配(pei)(pei)售(shou)(shou)(shou)價）認(ren)(ren)購(gou)(gou)認(ren)(ren)購(gou)(gou)股(gu)(gu)(gu)份(fen)（相(xiang)(xiang)當(dang)于銷售(shou)(shou)(shou)股(gu)(gu)(gu)份(fen)的(de)數目）。所得款項凈額估計約(yue)15.535億港(gang)元，公(gong)司擬將約(yue)90%用(yong)于研(yan)發相(xiang)(xiang)關開支，包括推(tui)動在(zai)中(zhong)國及(ji)美國針對(dui)研(yan)發階段(duan)新(xin)藥(yao)的(de)臨床研(yan)究(jiu)，支持已批(pi)準的(de)創新(xin)藥(yao)物的(de)新(xin)適應癥擴展；約(yue)10%用(yong)于營運資金及(ji)其他一(yi)般(ban)企業用(yong)途。